Atossa Therapeutics

Atossa Therapeutics to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021

Retrieved on: 
Friday, May 14, 2021
Life sciences, Atossa Therapeutics, Biotechnology, Health sciences, Selective estrogen receptor modulators, Triphenylethylenes, Atossa, Biopharmaceutical, Endoxifen

b'SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that management will participate at the Investor Summit Conference on May 18, 2021.\nCEO Dr. Steven Quay and Kyle Guse, CFO and General Counsel will deliver a corporate presentation at 8:45am ET on May 18, 2021.\nInvestors can also request a one-on-one meeting with management to be arranged following the conclusion of the conference.\nAtossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19.

Key Points: 
  • b'SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that management will participate at the Investor Summit Conference on May 18, 2021.\nCEO Dr. Steven Quay and Kyle Guse, CFO and General Counsel will deliver a corporate presentation at 8:45am ET on May 18, 2021.\nInvestors can also request a one-on-one meeting with management to be arranged following the conclusion of the conference.\nAtossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19.
  • For more information, please visit www.atossatherapeutics.com\nForward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with development plans, any variation between interim, preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa\xe2\x80\x99s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, whether change in mammographic breast density is an approvable end point for oral Endoxifen, and other risks detailed from time to time in Atossa\xe2\x80\x99s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.\n'

Atossa Therapeutics Urges Shareholders to Vote on Proposals Ahead of its Annual Stockholder Meeting May 14, 2021 at 1:00 PM Pacific Time

Retrieved on: 
Tuesday, May 11, 2021
Life sciences, Atossa Therapeutics, Biotechnology, Health sciences, Selective estrogen receptor modulators, Triphenylethylenes, Atossa, Biopharmaceutical, Endoxifen

b'SEATTLE, May 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases urges stockholders to vote on proposals put forth in the proxy statement prior to the Company\xe2\x80\x99s May 14, 2021 annual stockholder meeting.\nAtossa stockholder as of the March 24, 2021 record date may vote by calling (833) 786-6488 Monday through Friday 9 a.m. to 9 p.m. Eastern Time.

Key Points: 
  • b'SEATTLE, May 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases urges stockholders to vote on proposals put forth in the proxy statement prior to the Company\xe2\x80\x99s May 14, 2021 annual stockholder meeting.\nAtossa stockholder as of the March 24, 2021 record date may vote by calling (833) 786-6488 Monday through Friday 9 a.m. to 9 p.m. Eastern Time.
  • Details of the proposals, the stockholder meeting, and additional information on how to vote your shares can be found in the proxy statement, found here .
  • Holders of approximately 17.3 million shares of Atossa common stock as of the record date have entered into lock-up and voting agreements which require that they vote at the annual stockholder meeting.\nAtossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19.
  • For more information, please visit www.atossatherapeutics.com\nForward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with development plans, any variation between interim, preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa\xe2\x80\x99s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, whether change in mammographic breast density is an approvable end point for oral Endoxifen, and other risks detailed from time to time in Atossa\xe2\x80\x99s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.\n'

Atossa Therapeutics CEO Dr. Steven Quay to Participate in Panel Discussion at Cello Health’s Cancer Progress Virtual Conference on May 6, 2021

Retrieved on: 
Friday, April 30, 2021
Life sciences, Biotechnology, Atossa Therapeutics, Health sciences, Atossa, Biopharmaceutical, Endoxifen

b'SEATTLE, April 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that Atossa CEO Dr. Steven Quay will participate in a panel discussion at Cello Health\xe2\x80\x99s Cancer Progress Virtual Conference on May 6, 2021 at 10:00 AM ET.

Key Points: 
  • b'SEATTLE, April 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that Atossa CEO Dr. Steven Quay will participate in a panel discussion at Cello Health\xe2\x80\x99s Cancer Progress Virtual Conference on May 6, 2021 at 10:00 AM ET.
  • The conference will be conducted from May 4-6, 2021.\nThe panel is titled, \xe2\x80\x9cInvesting in the Emerald City of Oncology Innovation: Platforms & Modalities & Targets, Oh My!\xe2\x80\x9d and also features speakers from multiple well-known venture investment funds.
  • For those interested in attending the conference, registration can be found here .\nAtossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19.
  • For more information, please visit www.atossatherapeutics.com\nForward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with development plans, any variation between interim, preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa\xe2\x80\x99s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, whether change in mammographic breast density is an approvable end point for oral Endoxifen, and other risks detailed from time to time in Atossa\xe2\x80\x99s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.\n'

Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

Retrieved on: 
Friday, March 12, 2021
Clinical research, Health sciences, Medical research, Design of experiments, Health, Clinical trials, Atossa Therapeutics, Placebo-controlled study, Placebo

"As the CRO for this important study, we congratulate Atossa Therapeutics on these impressive safety and tolerability clinical results.

Key Points: 
  • "As the CRO for this important study, we congratulate Atossa Therapeutics on these impressive safety and tolerability clinical results.
  • Atossa Therapeutics have tapped the full scope of our CRO services including ClinicReady, our scientific and medical affairs specialist team.
  • Atossa Therapeutics today announced final results from its Phase 1 double-blinded, randomized, placebo-controlled clinical study using Atossa's proprietary drug candidate AT-301 administered by nasal spray.
  • The Phase 1 study was a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects who were divided into two study groups.

Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen

Retrieved on: 
Wednesday, February 3, 2021
Selective estrogen receptor modulators, Triphenylethylenes, Atossa Therapeutics, Endoxifen, Cancer, Breast cancer, Health, Branches of biology, Clinical medicine

At the end of 2018, the FDA authorized a single-patient study under its Expanded Access, or compassionate use program, for this breast cancer patient to receive Atossas oral Endoxifen in the window of opportunity between diagnosis of breast cancer and surgery.

Key Points: 
  • At the end of 2018, the FDA authorized a single-patient study under its Expanded Access, or compassionate use program, for this breast cancer patient to receive Atossas oral Endoxifen in the window of opportunity between diagnosis of breast cancer and surgery.
  • She has now taken Atossas oral Endoxifen for approximately 26 months and is continuing to take oral Endoxifen daily under these authorizations.
  • We are very encouraged by this patients experience with our Endoxifen over the past two years.
  • Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.

Atossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding Warrants

Retrieved on: 
Friday, January 29, 2021
Atossa Therapeutics, Atossa, Royalty

The warrants were issued in financings in December 2020 and January 2021.

Key Points: 
  • The warrants were issued in financings in December 2020 and January 2021.
  • We completed financings with gross proceeds of approximately $60 million and in the past week have added an additional $21 million to our balance sheet through the exercise of outstanding warrants.
  • We look forward to the speed at which we can now advance our programs in 2021.
  • Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.